CSF3 and Thrombocytopenia: A phase Ib study combining gemcitabine or docetaxel with PR-104 reported DLTs of thrombocytopenia or neutropenia at PR-104 doses >200 mg/m2; however, addition of prophylactic granulocyte colony stimulating factor (G-CSF) permitted PR-104 dose escalation to 770 mg/m2 in combination with docetaxel [22].